Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Mark M. Yarchoan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4401-0748; OpenAlex author ID A5076456783. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 12

  1. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  2. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  3. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  4. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  5. Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial. Co-author DOI 10.1038/s41467-024-52528-7↗
  6. Spatial multi-omics reveal intratumoral humoral immunity niches associated with tertiary lymphoid structures in pancreatic cancer immunotherapy pathologic resp… Co-author DOI 10.1101/2024.09.22.613714↗
  7. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Co-author DOI 10.1080/2162402x.2021.2001159↗
  8. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Co-author DOI 10.1186/s13059-021-02363-6↗
  9. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. First author DOI 10.1172/jci.insight.122092↗
  10. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. Co-author DOI 10.1172/jci.insight.122857↗
  11. Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Last author DOI 10.21037/apc.2018.02.01↗
  12. Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Co-author DOI 10.18632/oncotarget.17237↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 11 shared papers, 2017–2026 · strength 1.48
  2. Won Jin Ho · 7 shared papers, 2021–2026 · strength 1.08
  3. Daniel A. Laheru · 7 shared papers, 2017–2026 · strength 0.99
  4. Nilofer Saba Azad · 6 shared papers, 2017–2026 · strength 0.89
  5. Neeha Zaidi · 6 shared papers, 2018–2026 · strength 0.85
  6. Marina Baretti · 5 shared papers, 2021–2026 · strength 0.83
  7. Luciane Tsukamoto Kagohara · 5 shared papers, 2021–2026 · strength 0.82
  8. Elana Judith Fertig · 5 shared papers, 2021–2026 · strength 0.78
  9. Hao Wang · 4 shared papers, 2025–2026 · strength 0.77
  10. Robert A. Anders · 4 shared papers, 2024–2026 · strength 0.71
  11. Amanda L. Huff · 4 shared papers, 2021–2026 · strength 0.68
  12. Saurav Daniel Haldar · 3 shared papers, 2026 · strength 0.58
  13. Katherine M. Bever · 3 shared papers, 2026 · strength 0.58
  14. Janelle Marie Montagne · 3 shared papers, 2024–2026 · strength 0.52
  15. Dimitrios N. Sidiropoulos · 3 shared papers, 2024–2026 · strength 0.51
  16. Lei Zheng · 4 shared papers, 2017–2025 · strength 0.49
  17. Matthew Z. Guo · 2 shared papers, 2025–2026 · strength 0.40
  18. Jae Woo Lee · 2 shared papers, 2026 · strength 0.38
  19. Thatcher Ross Heumann · 2 shared papers, 2026 · strength 0.38
  20. Jin Peng He · 3 shared papers, 2018–2025 · strength 0.36
  21. Richard Andrew Burkhart · 3 shared papers, 2018–2025 · strength 0.36
  22. Ana De Jesus‐Acosta · 3 shared papers, 2017–2025 · strength 0.33
  23. Michael Goggins · 2 shared papers, 2017–2026 · strength 0.27
  24. Nicole Groß · 2 shared papers, 2021–2024 · strength 0.26
  25. Dung Thi Le · 3 shared papers, 2017–2018 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.